SE0202110D0 - Iscom preparation and use thereof - Google Patents

Iscom preparation and use thereof

Info

Publication number
SE0202110D0
SE0202110D0 SE0202110A SE0202110A SE0202110D0 SE 0202110 D0 SE0202110 D0 SE 0202110D0 SE 0202110 A SE0202110 A SE 0202110A SE 0202110 A SE0202110 A SE 0202110A SE 0202110 D0 SE0202110 D0 SE 0202110D0
Authority
SE
Sweden
Prior art keywords
iscom
complexes
complex
mixture
parts
Prior art date
Application number
SE0202110A
Other languages
English (en)
Inventor
Bror Morein
Bengtsson Karin Loevgren
Original Assignee
Isconova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isconova Ab filed Critical Isconova Ab
Priority to SE0202110A priority Critical patent/SE0202110D0/sv
Publication of SE0202110D0 publication Critical patent/SE0202110D0/sv
Priority to US10/520,022 priority patent/US20060121065A1/en
Priority to AT03738849T priority patent/ATE434443T1/de
Priority to BRPI0312472A priority patent/BRPI0312472B8/pt
Priority to ES03738849T priority patent/ES2328474T3/es
Priority to CA2491457A priority patent/CA2491457C/en
Priority to DE60328108T priority patent/DE60328108D1/de
Priority to AU2003245220A priority patent/AU2003245220B2/en
Priority to NZ537661A priority patent/NZ537661A/en
Priority to JP2004519469A priority patent/JP4636877B2/ja
Priority to PCT/SE2003/001180 priority patent/WO2004004762A1/en
Priority to DK03738849T priority patent/DK1539231T3/da
Priority to EP03738849A priority patent/EP1539231B1/en
Priority to ZA200500073A priority patent/ZA200500073B/xx
Priority to US14/587,116 priority patent/US10729764B2/en
Priority to US16/823,836 priority patent/US20200215189A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SE0202110A 2002-07-05 2002-07-05 Iscom preparation and use thereof SE0202110D0 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE0202110A SE0202110D0 (sv) 2002-07-05 2002-07-05 Iscom preparation and use thereof
EP03738849A EP1539231B1 (en) 2002-07-05 2003-07-07 Iscom preparation and use thereof
DE60328108T DE60328108D1 (de) 2002-07-05 2003-07-07 Iscom-zubereitung und ihre verwendung
NZ537661A NZ537661A (en) 2002-07-05 2003-07-07 Iscom preparation and use thereof
BRPI0312472A BRPI0312472B8 (pt) 2002-07-05 2003-07-07 composição compreendendo dois complexos iscom diferentes
ES03738849T ES2328474T3 (es) 2002-07-05 2003-07-07 Preparacion de iscom y su utilizacion.
CA2491457A CA2491457C (en) 2002-07-05 2003-07-07 Iscom preparation and use thereof
US10/520,022 US20060121065A1 (en) 2002-07-05 2003-07-07 Iscom preparation and use thereof
AU2003245220A AU2003245220B2 (en) 2002-07-05 2003-07-07 Iscom preparation and use thereof
AT03738849T ATE434443T1 (de) 2002-07-05 2003-07-07 Iscom-zubereitung und ihre verwendung
JP2004519469A JP4636877B2 (ja) 2002-07-05 2003-07-07 免疫刺激複合体の調製及びその使用
PCT/SE2003/001180 WO2004004762A1 (en) 2002-07-05 2003-07-07 Iscom preparation and use thereof
DK03738849T DK1539231T3 (da) 2002-07-05 2003-07-07 Iscom-præparation og anvendelse deraf
ZA200500073A ZA200500073B (en) 2002-07-05 2005-01-04 Iscom preparation and use thereof.
US14/587,116 US10729764B2 (en) 2002-07-05 2014-12-31 ISCOM preparation and use thereof
US16/823,836 US20200215189A1 (en) 2002-07-05 2020-03-19 Iscom preparation and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202110A SE0202110D0 (sv) 2002-07-05 2002-07-05 Iscom preparation and use thereof

Publications (1)

Publication Number Publication Date
SE0202110D0 true SE0202110D0 (sv) 2002-07-05

Family

ID=20288449

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202110A SE0202110D0 (sv) 2002-07-05 2002-07-05 Iscom preparation and use thereof

Country Status (14)

Country Link
US (3) US20060121065A1 (sv)
EP (1) EP1539231B1 (sv)
JP (1) JP4636877B2 (sv)
AT (1) ATE434443T1 (sv)
AU (1) AU2003245220B2 (sv)
BR (1) BRPI0312472B8 (sv)
CA (1) CA2491457C (sv)
DE (1) DE60328108D1 (sv)
DK (1) DK1539231T3 (sv)
ES (1) ES2328474T3 (sv)
NZ (1) NZ537661A (sv)
SE (1) SE0202110D0 (sv)
WO (1) WO2004004762A1 (sv)
ZA (1) ZA200500073B (sv)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
WO2006078213A1 (en) 2005-01-20 2006-07-27 Isconova Ab Vaccine composition comprisinga fibronectin binding protein or a fibronectin binding peptide
EP1764369A1 (de) * 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
WO2008031878A1 (en) * 2006-09-15 2008-03-20 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
EP1902727A1 (de) * 2006-09-22 2008-03-26 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP3272359A1 (en) 2010-07-23 2018-01-24 Novavax AB Influenza vaccine
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
US10047116B2 (en) 2011-10-03 2018-08-14 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
US9452211B2 (en) 2011-11-28 2016-09-27 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
EP2827895B1 (en) 2012-03-22 2017-08-09 Janssen Vaccines & Prevention B.V. Vaccine against rsv
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
EP2953638B1 (en) 2013-02-07 2023-07-05 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
NZ630868A (en) 2013-03-08 2017-02-24 Janssen Vaccines & Prevention Bv Acellular pertussis vaccine
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
DK2988780T3 (en) 2013-04-25 2019-04-08 Janssen Vaccines & Prevention Bv STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES
AU2014273173B2 (en) 2013-05-30 2018-09-27 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
SG11201510216RA (en) 2013-06-17 2016-01-28 Crucell Holland Bv Stabilized soluble pre-fusion rsv f polypeptides
WO2015000831A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
EP3017040B1 (en) 2013-07-02 2018-06-06 Janssen Vaccines & Prevention B.V. Method for preparing virosomes
KR101821712B1 (ko) 2013-08-22 2018-01-24 주식회사 아데나 삼칠근 추출물, 비누풀잎 추출물, 검정콩 잎 추출물, 녹두 잎 추출물 및 호랑이콩 잎 추출물을 포함하는 Ｔｈ2-매개 면역 질환 개선, 예방 또는 치료용 조성물
EA038400B1 (ru) 2014-07-10 2021-08-23 Янссен Вэксинс Энд Превеншн Б.В. Полипептид стеблевого домена гемагглютинина вируса гриппа и его применение
HUE040440T2 (hu) 2014-11-04 2019-03-28 Janssen Vaccines & Prevention Bv Terápiás HPV16-oltóanyagok
WO2016166088A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
US10456462B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Preventions B.V. Vaccine against RSV
AU2016289496B2 (en) 2015-07-07 2021-02-04 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
WO2017029360A1 (en) 2015-08-20 2017-02-23 Janssen Vaccines & Prevention B.V. Therapeutic hpv18 vaccines
US10538557B2 (en) 2015-09-02 2020-01-21 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
IL303336A (en) 2015-09-03 2023-08-01 Novavax Inc Immune compositions with improved stability and immunogenicity
JP6817307B2 (ja) 2015-12-23 2021-01-20 ファイザー・インク Ｒｓｖ ｆタンパク質突然変異体
MD3439672T2 (ro) 2016-04-05 2021-04-30 Janssen Vaccines & Prevention Bv Proteine F RVS de pre-fuziune solubile stabilizate pentru utilizare în profilixia infecţiilor cu RSV
MY193584A (en) 2016-04-05 2022-10-19 Janssen Vaccines & Prevention Bv Vaccine against rsv
WO2017192418A1 (en) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
MX2018013817A (es) 2016-05-12 2019-03-21 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EA039124B1 (ru) 2016-05-30 2021-12-08 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные f-белки rsv до слияния
EP3472327B1 (en) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
CA3053212C (en) 2017-02-09 2021-04-13 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
JP7317796B2 (ja) 2017-07-24 2023-07-31 ノババックス，インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
US11229695B2 (en) 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
WO2019145310A1 (en) 2018-01-23 2019-08-01 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2019183063A1 (en) 2018-03-19 2019-09-26 Novavax, Inc. Multivalent influenza nanoparticle vaccines
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
WO2019224275A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
KR20210091749A (ko) 2018-11-13 2021-07-22 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합전 rsv f 단백질
EP3959228A1 (en) 2019-04-25 2022-03-02 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
KR20220008875A (ko) 2019-05-15 2022-01-21 얀센 백신스 앤드 프리벤션 비.브이. 계절성 인플루엔자 백신과 아데노바이러스 기반 호흡기 세포융합 바이러스 백신의 공동투여
CA3140234A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
AU2020342463A1 (en) 2019-09-05 2022-03-24 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
JP2023512519A (ja) 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
IL298055A (en) 2020-05-11 2023-01-01 Janssen Pharmaceuticals Inc Stabilized coronavirus spike protein fusion proteins
US20210347828A1 (en) 2020-05-11 2021-11-11 Janssen Pharmaceuticals, Inc. RNA Replicon Encoding a Stabilized Corona Virus Spike Protein
CA3183500A1 (en) 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2022002894A1 (en) 2020-06-29 2022-01-06 Janssen Vaccines & Prevention B.V. Vaccine combination against respiratory syncytial virus infection
MX2023000373A (es) 2020-07-06 2023-02-13 Janssen Pharmaceuticals Inc Proteinas de fusion de proteinas de la espicula de coronavirus estabilizadas.
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
EP4314019A2 (en) 2021-04-01 2024-02-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2023217988A1 (en) 2022-05-12 2023-11-16 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024017682A1 (en) 2022-07-18 2024-01-25 Janssen Vaccines & Prevention B.V. Rsv immunogens
WO2024030856A2 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2024104947A2 (en) 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
WO2024153674A1 (en) 2023-01-18 2024-07-25 Novavax AB Methods of quantifying saponins present in particles comprising saponin and lipid
US20240269263A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
WO2024175579A1 (en) 2023-02-21 2024-08-29 Janssen Vaccines & Prevention B.V. Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE71303T1 (de) * 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof

Also Published As

Publication number Publication date
DK1539231T3 (da) 2009-09-14
WO2004004762A1 (en) 2004-01-15
US20200215189A1 (en) 2020-07-09
BR0312472A (pt) 2005-04-26
US10729764B2 (en) 2020-08-04
ZA200500073B (en) 2006-02-22
ES2328474T3 (es) 2009-11-13
EP1539231A1 (en) 2005-06-15
NZ537661A (en) 2008-08-29
AU2003245220B2 (en) 2009-04-23
US20060121065A1 (en) 2006-06-08
EP1539231B1 (en) 2009-06-24
JP4636877B2 (ja) 2011-02-23
JP2006511451A (ja) 2006-04-06
CA2491457A1 (en) 2004-01-15
BRPI0312472B8 (pt) 2021-05-25
BRPI0312472B1 (pt) 2019-07-16
US20150209425A1 (en) 2015-07-30
CA2491457C (en) 2012-09-04
ATE434443T1 (de) 2009-07-15
AU2003245220A1 (en) 2004-01-23
DE60328108D1 (de) 2009-08-06

Similar Documents

Publication Publication Date Title
SE0202110D0 (sv) Iscom preparation and use thereof
NZ512011A (en) Improved saponin adjuvant compositions and methods relating thereto
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
MY129263A (en) Vaccine composition
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
NO20031646L (no) Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol
NO20005051L (no) Adjuvantsammensetninger
NO20074392L (no) Vaksine
TW200616661A (en) HER2 antibody composition
MXPA04001224A (es) Agentes para incrementar la respuesta inmune.
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
DK1089968T3 (da) Thyroideahormonanaloger og fremgangsmåder til deres fremstilling
NO20015074D0 (no) Nye sammensetninger
WO2022249106A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
WO2022249107A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2021158755A3 (en) Leptospiral proteins and uses thereof
WO2007031334A3 (en) Vaccines comprising truncated hbc core protein plus saponin-based adjuvants
WO2023235660A3 (en) Flavivirus immunogens and vaccine compositions and methods of using the same
WO2004098529A3 (en) Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
MX2024008039A (es) Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y usos de los mismos.